How has been the historical performance of the Norris Medicines?

Answer:The historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years.

Breakdown:
Norris Medicines has experienced a significant decline in net sales from Rs 16.27 crore in March 2019 to Rs 5.82 crore in March 2025. This downward trend is mirrored in total operating income, which also decreased from Rs 16.27 crore in March 2019 to Rs 5.82 crore in March 2025. The company's total expenditure, excluding depreciation, has fluctuated but generally decreased from Rs 16.88 crore in March 2019 to Rs 6.08 crore in March 2025. Operating profit has been negative in recent years, with a loss of Rs 0.20 crore in March 2025 compared to a profit of Rs 0.93 crore in March 2023. The profit before tax has also remained negative, with losses ranging from Rs 1.00 crore to Rs 3.99 crore over the years. Consequently, the net profit has consistently been negative, culminating in a loss of Rs 1.24 crore in March 2025. The company's total liabilities have increased from Rs 17.57 crore in March 2019 to Rs 21.52 crore in March 2024, while total assets have slightly decreased from Rs 17.57 crore to Rs 13.22 crore in the same period. Cash flow from operating activities has been stagnant, with no cash inflow reported in recent years. Overall, Norris Medicines has faced challenges in maintaining sales and profitability, leading to a deteriorating financial position.